About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company's focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations. Its generic products include Esterified Estrogen with Methyltestosterone, Etodolac, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup, Nimodipine, Opium Tincture, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Lithobid, Reglan and Vancocin. It has over two pharmaceutical manufacturing facilities located in Baudette, Minnesota that are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products. Its two facilities have a combined manufacturing, packaging and laboratory capacity totaling approximately 173,000 square feet.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: ANIP
- Previous Close: $59.62
- 50 Day Moving Average: $60.75
- 200 Day Moving Average: $62.16
- 52-Week Range: $30.00 - $70.92
- Trailing P/E Ratio: 86.37
- Foreward P/E Ratio: 13.43
- P/E Growth: 0.96
- Market Cap: $683.10M
- Outstanding Shares: 11,580,000
- Beta: 3
- Net Margins: 7.28%
- Return on Equity: 21.84%
- Return on Assets: 11.84%
Companies Related to ANI Pharmaceuticals:
- Debt-to-Equity Ratio: 0.70%
- Current Ratio: 3.13%
- Quick Ratio: 2.20%
What is ANI Pharmaceuticals' stock symbol?
ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."
Where is ANI Pharmaceuticals' stock going? Where will ANI Pharmaceuticals' stock price be in 2017?
6 analysts have issued 12-month price objectives for ANI Pharmaceuticals' shares. Their forecasts range from $65.00 to $80.00. On average, they anticipate ANI Pharmaceuticals' share price to reach $70.60 in the next twelve months.
When will ANI Pharmaceuticals announce their earnings?
ANI Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March, 2nd 2017.
Who owns ANI Pharmaceuticals stock?
ANI Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include State Street Corp (2.71%), Renaissance Technologies LLC (2.01%), Fiera Capital Corp (1.37%), Dimensional Fund Advisors LP (0.79%), Foresters Investment Management Company Inc. (0.76%) and GSA Capital Partners LLP (0.46%). Company insiders that own ANI Pharmaceuticals stock include Arthur Przybyl, James G Marken and Robert W Schrepfer.
Who sold ANI Pharmaceuticals stock? Who is selling ANI Pharmaceuticals stock?
ANI Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Fiera Capital Corp, State Street Corp, Cadence Capital Management LLC, Federated Investors Inc. PA, Tudor Investment Corp Et Al, GSA Capital Partners LLP, Envestnet Asset Management Inc. and Third Avenue Management LLC. Company insiders that have sold ANI Pharmaceuticals stock in the last year include Arthur Przybyl and Robert W Schrepfer.
Who bought ANI Pharmaceuticals stock? Who is buying ANI Pharmaceuticals stock?
ANI Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Renaissance Technologies LLC, Guggenheim Capital LLC, AQR Capital Management LLC, Comerica Bank and Thrivent Financial for Lutherans.
How do I buy ANI Pharmaceuticals stock?
Shares of ANI Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of ANI Pharmaceuticals stock cost?
One share of ANI Pharmaceuticals stock can currently be purchased for approximately $59.62.